BRPI1008023B8 - Forma de dosagem sólida - Google Patents

Forma de dosagem sólida

Info

Publication number
BRPI1008023B8
BRPI1008023B8 BRPI1008023A BRPI1008023A BRPI1008023B8 BR PI1008023 B8 BRPI1008023 B8 BR PI1008023B8 BR PI1008023 A BRPI1008023 A BR PI1008023A BR PI1008023 A BRPI1008023 A BR PI1008023A BR PI1008023 B8 BRPI1008023 B8 BR PI1008023B8
Authority
BR
Brazil
Prior art keywords
solid dosage
dosage form
formulations
bardoxolone
particles
Prior art date
Application number
BRPI1008023A
Other languages
English (en)
Inventor
Zhang Jiang
J Meyer Colin
Original Assignee
Reata Pharmaceuticals Inc
Reata Pharmaceuticals Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1008023(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reata Pharmaceuticals Inc, Reata Pharmaceuticals Holdings Llc filed Critical Reata Pharmaceuticals Inc
Publication of BRPI1008023A2 publication Critical patent/BRPI1008023A2/pt
Publication of BRPI1008023B1 publication Critical patent/BRPI1008023B1/pt
Publication of BRPI1008023B8 publication Critical patent/BRPI1008023B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forma de Dosagem Sólida. Formulações farmacêuticas exibem um Cmax desejavelmente baixo, dentre outras propriedades, que contêm partículas de bardoxolona metil amorfa, seja em forma pura ou na forma de uma dispersão sólida, misturada com partículas de um agente de ligação hidrofílico. Essas formulações possuem a vantagem de biodisponibilidade oral mais alta, relativo para formulações com base na forma cristalina de bardoxolona metil.
BRPI1008023A 2009-02-13 2010-02-12 Forma de dosagem sólida BRPI1008023B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15260809P 2009-02-13 2009-02-13
PCT/US2010/024127 WO2010093944A2 (en) 2009-02-13 2010-02-12 Delayed release, oral dosage compositions that contain amorphous cddo-me

Publications (3)

Publication Number Publication Date
BRPI1008023A2 BRPI1008023A2 (pt) 2016-03-15
BRPI1008023B1 BRPI1008023B1 (pt) 2019-12-31
BRPI1008023B8 true BRPI1008023B8 (pt) 2023-04-11

Family

ID=42335073

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008023A BRPI1008023B8 (pt) 2009-02-13 2010-02-12 Forma de dosagem sólida

Country Status (30)

Country Link
US (2) US8747901B2 (pt)
EP (2) EP2395979B1 (pt)
JP (1) JP5775464B2 (pt)
KR (2) KR20140016441A (pt)
CN (2) CN105232471A (pt)
AU (1) AU2010213594B2 (pt)
BR (1) BRPI1008023B8 (pt)
CA (1) CA2752048C (pt)
CO (1) CO6361904A2 (pt)
CY (2) CY1119595T1 (pt)
DK (2) DK2395979T3 (pt)
EA (1) EA023652B1 (pt)
ES (2) ES2646816T3 (pt)
HK (1) HK1220130A1 (pt)
HR (2) HRP20171639T1 (pt)
HU (2) HUE035013T2 (pt)
IL (1) IL214258A (pt)
LT (2) LT3254675T (pt)
MX (1) MX2011008344A (pt)
MY (1) MY173715A (pt)
NO (1) NO2395979T3 (pt)
NZ (1) NZ594488A (pt)
PL (2) PL3254675T3 (pt)
PT (2) PT2395979T (pt)
SG (1) SG173601A1 (pt)
SI (2) SI2395979T1 (pt)
SM (2) SMT201900432T1 (pt)
TR (1) TR201909743T4 (pt)
WO (1) WO2010093944A2 (pt)
ZA (1) ZA201105630B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
ME03529B (me) 2008-01-11 2020-04-20 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
HUE033288T2 (en) 2008-04-18 2017-11-28 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives
RS58392B1 (sr) 2008-04-18 2019-04-30 Reata Pharmaceuticals Inc Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17
TW201006474A (en) 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
ES2449396T3 (es) 2008-07-22 2014-03-19 Trustees Of Dartmouth College Cianoenonas monocíclicas y métodos de uso de las mismas
SG173601A1 (en) 2009-02-13 2011-09-29 Reata Pharmaceuticals Inc Delayed release, oral dosage compositions that contain amorphous cddo-me
AU2011240690C1 (en) 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
ES2653717T3 (es) 2010-12-17 2018-02-08 Reata Pharmaceuticals, Inc. Pirazolil- y pirimidinil-enonas tricíclicas como moduladores antioxidantes de la inflamación
EA026847B1 (ru) 2011-03-11 2017-05-31 Рита Фармасьютикалз, Инк. C4-монометилтритерпеноидные производные и способы их применения
CN103156861B (zh) * 2011-12-08 2015-11-25 陈丽梅 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
EP2841445B1 (en) 2012-04-27 2017-06-14 Reata Pharmaceuticals, Inc. 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
TWI630212B (zh) 2012-09-10 2018-07-21 瑞塔醫藥有限責任公司 丁香油素（ｏｌｅａｎｏｌｉｃ ａｃｉｄ）之ｃ１７－烷二基與烯二基衍生物及其使用方法
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
IL285832B2 (en) 2013-08-23 2024-01-01 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EP3212195A4 (en) 2014-10-31 2018-06-06 The Regents of The University of California Compositions and methods for treating hiv-associated cognitive dysfunction
AU2016219109B2 (en) 2015-02-12 2020-05-14 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant iflammation modulators
BR112018005861B1 (pt) 2015-09-23 2022-11-22 Reata Pharmaceuticals, Inc Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals, Inc. métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2019014412A1 (en) 2017-07-13 2019-01-17 Pliva Hrvatska D.O.O. NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE
EP3773509B1 (en) 2018-04-06 2023-11-01 Capsugel Belgium NV Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
US11993574B2 (en) 2018-06-15 2024-05-28 Reata Pharmaceuticals, Inc Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
WO2020111089A1 (ja) 2018-11-27 2020-06-04 協和キリン株式会社 医薬組成物
SG11202112464PA (en) * 2019-05-31 2021-12-30 Denali Therapeutics Inc Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment
CN120248001A (zh) 2019-07-19 2025-07-04 里亚塔医药公司 C17极性的-取代的杂芳族合成三萜类化合物及其使用方法
CA3177913A1 (en) 2020-05-09 2021-11-18 Deborah FERGUSON Methods of treating covid-19 using bardoxolone methyl or analogs thereof
US20240293351A1 (en) 2020-12-11 2024-09-05 Reata Pharmaceuticals Holdings, LLC Methods of administering synthetic triterpenoids
CN114558019A (zh) * 2022-03-26 2022-05-31 中国科学院昆明动物研究所 一种Rab13基因抑制剂及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
JP2008110962A (ja) * 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
JP4315182B2 (ja) * 2006-10-30 2009-08-19 ミツミ電機株式会社 カメラモジュール
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
ME03529B (me) * 2008-01-11 2020-04-20 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
SG173601A1 (en) 2009-02-13 2011-09-29 Reata Pharmaceuticals Inc Delayed release, oral dosage compositions that contain amorphous cddo-me

Also Published As

Publication number Publication date
WO2010093944A3 (en) 2011-08-11
NZ594488A (en) 2013-10-25
CO6361904A2 (es) 2012-01-20
HRP20171639T1 (hr) 2017-12-15
EA023652B1 (ru) 2016-06-30
HUE035013T2 (en) 2018-05-02
SG173601A1 (en) 2011-09-29
WO2010093944A2 (en) 2010-08-19
EP3254675A1 (en) 2017-12-13
CA2752048A1 (en) 2010-08-19
SI2395979T1 (sl) 2017-12-29
KR101483203B1 (ko) 2015-01-15
PT2395979T (pt) 2017-11-16
JP2012518008A (ja) 2012-08-09
MY173715A (en) 2020-02-18
EA201190092A1 (ru) 2012-02-28
DK2395979T3 (da) 2017-11-27
PT3254675T (pt) 2019-06-14
US20140235711A1 (en) 2014-08-21
SMT201900432T1 (it) 2019-09-09
IL214258A0 (en) 2011-09-27
PL3254675T3 (pl) 2019-09-30
SMT201700527T1 (it) 2018-01-11
LT2395979T (lt) 2017-12-11
CN105232471A (zh) 2016-01-13
HRP20191092T1 (hr) 2019-11-29
HK1220130A1 (zh) 2017-04-28
KR20140016441A (ko) 2014-02-07
US20120022156A1 (en) 2012-01-26
NO2395979T3 (pt) 2018-01-20
EP2395979B1 (en) 2017-08-23
IL214258A (en) 2017-06-29
BRPI1008023A2 (pt) 2016-03-15
MX2011008344A (es) 2011-09-29
AU2010213594B2 (en) 2013-11-14
DK3254675T3 (da) 2019-06-24
CY1122066T1 (el) 2020-11-25
CA2752048C (en) 2014-11-25
US8747901B2 (en) 2014-06-10
EP3254675B1 (en) 2019-05-15
US9155721B2 (en) 2015-10-13
EP2395979A2 (en) 2011-12-21
SI3254675T1 (sl) 2019-08-30
ES2731601T3 (es) 2019-11-18
AU2010213594A1 (en) 2011-08-18
ES2646816T3 (es) 2017-12-18
HUE044005T2 (hu) 2019-09-30
CY1119595T1 (el) 2018-03-07
PL2395979T3 (pl) 2018-02-28
ZA201105630B (en) 2012-04-25
CN102387789A (zh) 2012-03-21
BRPI1008023B1 (pt) 2019-12-31
LT3254675T (lt) 2019-06-25
KR20110118721A (ko) 2011-10-31
TR201909743T4 (tr) 2019-07-22
JP5775464B2 (ja) 2015-09-09

Similar Documents

Publication Publication Date Title
CY1122066T1 (el) Χορηγουμενες απο το στομα συνθεσεις καθυστερημενης εκλυσης που περιεχουν αμορφο cddo-me
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
MX2010005346A (es) Composiciones farmaceuticas.
WO2011110854A3 (en) The use of amisulpride as an anti-emetic
BR112012031500A8 (pt) Composições sólidas
BRPI0819936A2 (pt) Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação.
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
BR112013004016A2 (pt) formulações á base de nalbufina e as respectivas utilizações
BRPI0817503B8 (pt) derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
MY160340A (en) Pharmaceutical formulation 514
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
MX2023008180A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
EP2251011A4 (en) SOLID PREPARATION FOR ORAL ADMINISTRATION
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
ECSP088716A (es) Medicamentos que contienen fluoroquinolonas
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
PT103884A (pt) Composições de libertação prolongada e métodos para a sua preparação
MX2012013021A (es) Formulaciones resistentes a alcohol.
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
MX2013004972A (es) Formulaciones que comprenden polietilenglicol.
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
MX371349B (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
EP2497464A3 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: REATA PHARMACEUTICALS HOLDINGS, LLC (US)